Cash Flow Statement
Growth Metrics

Mimedx (MDXG) Gross Margin (2011 - 2026)

Mimedx recorded quarterly Gross Margin of 70.56% in Q1 2026, down 15.87% quarter-over-quarter from 83.86% in Q4 2025, and down 1067.0% year-over-year from 7.3% in Q1 2025.

Mimedx's Gross Margin history runs 16 years deep, the most recent figure standing at 70.56% for Q1 2026.

  • In Q1 2026, Gross Margin fell 1067.0% year-over-year to 70.56%; the TTM figure through Mar 2026 stood at 81.04% (down 90.0% YoY), while the FY2025 annual figure was 82.56%, down 22.0% from the prior year.
  • Gross Margin came in at 70.56% for Q1 2026 at Mimedx, down from 83.86% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 84.67% in Q1 2024 to a low of 70.56% in Q1 2026.
  • A 5-year average of 81.85% and a median of 82.32% in 2022 frame the typical range for Gross Margin.
  • Across the five-year window, Gross Margin surged 338 bps in 2023 and slumped 1067 bps in 2026, its largest moves.
  • Mimedx's Gross Margin stood at 80.68% in 2022, then increased by 4 bps to 84.06% in 2023, then slipped by 3 bps to 81.8% in 2024, then increased by 3 bps to 83.86% in 2025, then declined by 16 bps to 70.56% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods registered 70.56%, 83.86%, and 83.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn 70.56%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 70.56%
Dec 31, 2025 83.86%
Sep 30, 2025 83.54%
Jun 30, 2025 81.05%
Mar 31, 2025 81.23%
Dec 31, 2024 81.80%
Sep 30, 2024 81.77%
Jun 30, 2024 82.97%
Mar 31, 2024 84.67%
Dec 31, 2023 84.06%
Sep 30, 2023 81.90%
Jun 30, 2023 83.28%
Mar 31, 2023 82.67%
Dec 31, 2022 80.68%
Sep 30, 2022 81.99%
Jun 30, 2022 82.32%
Mar 31, 2022 83.13%
Dec 31, 2021 86.03%
Sep 30, 2021 83.94%
Jun 30, 2021 81.28%
Mar 31, 2021 83.92%
Dec 31, 2020 84.22%
Sep 30, 2020 84.00%
Jun 30, 2020 84.72%
Mar 31, 2020 83.76%
Dec 31, 2019 83.37%
Sep 30, 2019 85.14%
Jun 30, 2019 85.54%
Mar 31, 2019 88.85%
Dec 31, 2018 88.76%
Sep 30, 2018 91.54%
Jun 30, 2018 90.28%
Mar 31, 2018 88.88%
Dec 31, 2017 89.30%
Sep 30, 2017 88.93%
Jun 30, 2017 89.46%
Mar 31, 2017 88.33%
Dec 31, 2016 87.02%
Sep 30, 2016 87.59%
Jun 30, 2016 87.11%
Mar 31, 2016 85.11%
Dec 31, 2015 90.38%
Sep 30, 2015 89.84%
Jun 30, 2015 88.86%
Mar 31, 2015 87.37%
Dec 31, 2014 90.90%
Sep 30, 2014 90.01%
Jun 30, 2014 89.29%
Mar 31, 2014 84.78%
Dec 31, 2013 82.71%
Sep 30, 2013 86.88%
Jun 30, 2013 83.73%
Mar 31, 2013 83.52%
Dec 31, 2012 83.93%
Sep 30, 2012 82.08%
Jun 30, 2012 77.17%
Mar 31, 2012 74.12%
Dec 31, 2011 65.23%
Sep 30, 2011 58.81%
Jun 30, 2011 56.21%
Mar 31, 2011 31.95%